ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, adult
Results 1-25 of 534 for your search:
Start Over
Autologous Peripheral Blood Stem Cell Transplant in Treating Patients with Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT 2004-24, NCI-2010-01414, 0508M72589, 2005LS048, UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UTX-TGR-205, NCI-2016-01433, NCT02793583
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 20150292, NCI-2017-00688, 2016-002044-16, NCT02910063
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PIX306 (PIX-R Trial), NCI-2012-00808, PIX306, NCT01321541
Double Cord Versus Haploidentical (BMT CTN 1101)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 5U24CA076518, 715, NCT01597778
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IELSG37, NCI-2014-01062, NCT01599559
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Enrolling by invitation
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR100955, NCI-2013-02262, 2012-004225-24, PCI-32765CAN3001, NCT01804686
Tacrolimus and Methotrexate with or without Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host-Disease in Patients with Hematological Malignancy Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Supportive care
Age: 70 and under
Trial IDs: CASE 6Z13, NCI-2013-01800, NCT01951885
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-5013-NHL-008, NCI-2015-00708, NCT01996865
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: IPI-145-12, NCI-2014-02041, NCT02049515
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B3281006, NCI-2015-00476, 2014-000132-41, REFLECTIONS, NCT02213263
To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CT-P10 3.4, NCI-2016-00728, NCT02260804
Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: CC-5013-DLC-002, NCI-2015-00282, 2013-004054-21, NCT02285062
Rituximab with or without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients with Untreated Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LS138D, NCI-2014-02476, NCT02320292
Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17067, NCI-2015-01865, 2013-003893-29, NCT02367040
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Dose Optimization Study of Idelalisib in Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-313-1580, NCI-2015-01816, 2015-000366-66, NCT02536300
A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: CR107047, NCI-2016-00410, 2015-001630-21, 39039039STM4001, NCT02555878
Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 to 60
Trial IDs: GC P#05.01.020, NCI-2016-01518, NCT02730299
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: B9991011, NCI-2017-00031, 2016-002904-15, NCT02951156
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 60 and over
Trial IDs: PCYC-1141-CA, NCI-2017-00193, NCT02947347
Start Over